Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.34 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18697905 | 1.00 | ALDH1A1 (0.38) | ALDH1A1RIPK1TNK2HSPA2ABCB1 | |
| SCHEMBL14996153 | 0.91 | ALDH1A1 (0.36) | ALDH1A1RIPK1TNK2 | |
| SCHEMBL24791260 | 0.91 | ALDH1A1 (0.36) | ALDH1A1RIPK1TNK2 | |
| SCHEMBL881372 | 0.91 | ALDH1A1 (0.36) | ALDH1A1RIPK1TNK2 | |
| SCHEMBL24168927 | 0.89 | ALDH1A1 (0.35) | ALDH1A1RIPK1TNK2SLC22A1 | |
| SCHEMBL10187389 | 0.84 | NPC1 (0.39) | ALDH1A1RIPK1TNK2 | |
| SCHEMBL17617320 | 0.84 | ALDH1A1 (0.36) | ALDH1A1RIPK1TNK2 | |
| SCHEMBL12398186 | 0.84 | RIPK1 (0.35) | RIPK1TNK2 | |
| SCHEMBL15084410 | 0.84 | RIPK1 (0.35) | RIPK1TNK2 | |
| SCHEMBL10171966 | 0.83 | ALDH1A1 (0.36) | ALDH1A1RIPK1TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | ALDH1A1 2219/4885RIPK1 2571/4885TNK2 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.